3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
3
Phase 3
2
Phase 1/2
2
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
6
Head and Neck Neoplasms
6
Lung Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Skin Neoplasms
2
Recurrence
2
Cholangiocarcinoma
2
Advanced Solid Tumor
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous NSCLC
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Mouth Neoplasms
1
Mesothelioma
1
Liver Neoplasms
1
Laryngeal Neoplasms
1
Laryngeal Diseases
1
Klatskin Tumor
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Interventions
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
(225)Ac-DOTA-c(RGDyK)
2
pembrolizumab
1
durvalumab
1
atezolizumab
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Pilocarpine
1
Magnetic Resonance Spectroscopy
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hypopharyngeal Neoplasms
×
pembrolizumab
×
Clear all
NCT06295731
2026-05-08
HexAgon-HN
Inhibrx Biosciences, Inc
Phase 2/3
Active not recruiting
410 enrolled